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EXTENDED REPORT
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Aim: To evaluate the possibility of translocating autologous peripheral retinal pigment epithelial (RPE) cells
and enhance their adhesion to improve functional outcome after choroidal neovascular membrane
extraction in patients with subfoveal neovascular membranes.
Methods: A prospective, non-controlled surgical study in eight consecutive patients operated between
February and July 2001 with final data monitoring in July 2002. All patients had mixed subfoveal
membranes of 2–4 disc diameters. Functional tests included Snellen vision and central fixation testing.
During vitrectomy, after the extraction of the neovascular complex, 86104–166104 RPE cells were
removed from the periphery and translocated under the macula following the submacular injection of 2 mg
of poly-L-lysine to promote adhesion of the cells.
Results: With a follow up ranging from 3 months to 16 months, a pigmented area was seen in the
extraction bed of the neovascular membrane in only one patient. Fixation was at the edge of the extraction
bed in three patients. Vision remained the same in five patients and deteriorated in three (all with retinal
detachment). Retinal detachment due to proliferative vitreoretinopathy occurred in three patients.
Conclusions: The translocation of autologous peripheral RPE cells after membrane extraction was
technically possible in a sterile manner, but was associated with a high proliferative vitreoretinopathy rate
and in the present series had no measurable positive effect on functional outcome.
A
ge related macular degeneration (ARMD) is the leading
cause of visual loss in Europe and North America in
patients aged over 75, and in the majority of patients
legal blindness is due to choroidal neovascularisation.1
For small subfoveal neovascular membranes laser coagula-
tion was shown to be better than no treatment 2 years after
treatment.2 Photodynamic therapy (PDT) has been shown to
have better results than controls in patients with a
predominantly classic subfoveal membrane.3 4 As there is no
evidence based treatment available for large, occult subfoveal
neovascularisations, several non-controlled surgical
approaches have been reported in such patients. In ARMD
malfunction of the retinal pigment epithelium (RPE)-Bruch’s
membrane-choriocapillaris complex precedes the loss of
macular photoreceptors. In its exudative form, visual loss is
accelerated by choroidal neovascular invasion of Bruch’s
membrane, under the RPE and into the subretinal space.
Surgical removal of such neovascular membranes in patients
with ARMD invariably leads to damage of the RPE, as well as
the Bruch’s membrane-choriocapillary complex.5–7
Spontaneous RPE cell repopulation of the damaged area is
ineffective or too late, if at all present.8 9 Nevertheless, a
controlled trial is under way which studies simple subma-
cular membrane extraction.10
Macular rotation is a conceptually promising approach by
creating a fresh undersurface.11 A tilted image in successful
cases and a high percentage of vision threatening complica-
tions because of proliferative vitreoretinopathy (PVR), how-
ever, are drawbacks of this technique.12
Functioning RPE cells may be trophic for the re-establish-
ment of Bruch’s membrane and choriocapillaris.13 14
Moreover, in animal studies subretinal RPE injection was
able to postpone photoreceptor death in RCS rats.15
Consequently, other modifications to recreate the under-
layer under the macula have included the injection of a
homologous fetal cell patch.16 Its lack of success was partly
attributed to a chronic host versus graft rejection. Recently,
Weichel et al reported the lack of functional improvement
after the injection of HLA matched homologous RPE cells.17
Therefore, several authors used autologous cells: full
thickness en bloc translocation of adjacent macular chor-
oid-choriocapillary-Bruch’s membrane and RPE18;—translo-
cation by blunt needle aspiration and reinjection of mid-
peripheral RPE cells19—as well as the translocation of IPE
cells 17 For the last two approaches, however, adherence of
the injected cells to the damaged Bruch’s membrane remains
uncertain.
We have chosen to translocate peripheral autologous RPE
cells. We further tried to enhance RPE cell adherence by the
use of poly-L-lysine. Here we report the results of this
approach in a case series of eight patients with a subfoveal
neovascular membrane.
Patients and methods
Patients with a subfoveal choroidal neovascular membrane
that was more than 50% occult on fundus fluorescein
angiography (FFA) and larger than 2 disc diameters, with
or without submacular blood, were eligible for RPE translo-
cation. Eight patients were included in the study, from 29
January 2001 to 2 July 2001. This study had been approved by
the institutional board and written informed consent was
obtained from all patients, in accordance with the ethical
standards laid down in the 1964 Declaration of Helsinki.
Preoperative examination included history taking, Snellen
vision and a dilated pupil fundus examination, including
FFA. Postoperative visits were scheduled at 1, 3, and 6 weeks,
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3, 6, 9, and 12 months. The final date of monitoring was 30
July 2002. During each visit Snellen vision testing and a
comprehensive examination were performed. At 3, 6, and
12 months fundus pictures were taken and central fixation
was tested with the smallest spot (500 mm) of the Haag-
Straat slit lamp.
Preoperative measures
Three weeks preoperatively argon green laser coagulation
retinopexy was performed to wall off the inferior peripheral
retina in preparation of the planned peripheral retinectomy.
Three hours before surgery, blood was collected from the
patient to obtain autologous serum after clotting.
Surgery
After the induction of a posterior vitreous detachment a
complete vitrectomy was performed and a peripheral retinal
detachment was created in the walled off inferior retina by
the transretinal injection of Ringer’s solution into the
subretinal space. The detached retina was removed up to
the ora serrata with the vitrectome. If the patient was phakic,
lensectomy was performed at this stage.
Harvesting and analysis of RPE cells
We modified a bent 21 gauge aspiration canula by placing a
Nylon 8-0 loop on top and connected it to a 10 ml syringe.
The RPE cells were gently scraped off Bruch’s membrane and
aspirated through the canula. We collected 20 ml Ringer/RPE
aspirate. The cell aspirate was injected into a closed sterile
30 ml centrifuge tube and autologous serum (10%) was
added to prevent adherence of the cells to the tubing.20 After
centrifuging (3 g, 5 minutes) within a sterile holder the
supernatant was aspirated by the surgeon. The cell pellet was
resuspended in the remaining drop of supernatant and
aspirated in a subretinal canula with a 3 mm silicone tube
transparent extension. The cells remaining in the centrifuge
tube were counted in a counting chamber, analysed for
viability (morphology by phase contrast microscopy, trypan
blue exclusion staining) and seeded into culture discs after
the addition of Dulbecco’s modified essential medium
(DMEM).
Through a paramacular retinotomy the choroidal mem-
brane was removed from the subretinal space with a
subretinal forceps.
Poly-L-lysine (0.2 ml, 0.1 mg/ml) was injected under the
macula through the existing retinotomy. We tried to
minimise reflux through the retinotomy by injecting through
a third sclerotomy a 1 ml perfluorocarbon (PFCL) bubble
over the retinotomy with the injecting canula already
inserted under the macula.
After 5 minutes RPE cells were injected subfoveally, again
using a PFCL bubble to minimise reflux. Video sequences
were made during cell injection, to document proper
subretinal injection.
Either a 15% mixture of C3F8 gas or a silicone oil
tamponade was used and additional laser applied at the
peripheral retinectomy site. In gas filled eyes, an iris claw
fixated IOL was inserted; in silicone filled eyes an IOL was
inserted at the second surgery when we removed silicone oil.
The patient was instructed to remain supine as much as
possible during the first 24 hours.
Reoperations were performed for retinal detachments or
the removal of silicone oil with secondary intraocular lens
implantation.
RESULTS
Seven patients had ARMD in both eyes, with a fibrovascular
scar in the fellow eye in five patients (table 1). One 37 year
old woman had a subfoveal membrane secondary to
presumed ocular histoplasmosis syndrome (POHS).
The preoperative duration of visual loss in the operated eye
ranged from 8 weeks to 6 months. Visual acuity of the
operated eye ranged from counting fingers (CF) at 1 metre to
6/120.
Preoperative FFAs were obtained in all patients. Membrane
size ranged from 2–4 disc diameters. Subretinal blood was
present in six patients.
The number of cells analysed per patients varied from
12.56103 to 706103. Trypan blue exclusion staining revealed
that over 90% of cells were viable.
The heavily pigmented cells we plated adhered to the dish
for 5–28 days. Only the cells of patient 4 grew to confluence,
with a hexagonal pattern characteristic for RPE cells.
Preoperative course
Subretinal cell injection appeared successful in all patients
(also on reviewing the video recordings) except for patient 2
where possible reflux was noticed during cell injection,
although at the time we thought this could have been
simulated by subretinal blood egressing.
Silicone oil was used as a tamponade in one patient
(patient 3), in whom the preoperatively applied laser barrier
proved to be ineffective to prevent retinal detachment from
the retinectomy site during surgery; a 15% C3F8/air mixture
was used in the other seven patients (table 1).
Postoperative course
Retinal detachment developed due to proliferative vitreo-
retinopathy (PVR) in three patients, who underwent a second
vitrectomy with silicone oil tamponade.
Follow up of patients 1 and 3 was only 3 months, because
both died. In the other six patients, minimal follow up was
12 months (range 12–16 months). Snellen visual acuity at 3,
6, 9, or 12 months did not show a two line improvement in
any patient. In patients 2 and 7 visual loss was clearly caused
by the retinal detachment and PVR. These two patients, as
well as patient 4, did subjectively worse. Patients 3, 6, and 8
reported some subjective improvement.
Only in patient 8 was a pigmented area noted under the
retina within the membranectomy site. A slight increase in
pigmentation was noted during 12 months of follow up; the
area of atrophy of choriocapillaris remained unchanged.
Fixation at the edge of the extraction bed of the
neovascular membrane was noticed in patients 5, 6, and 8,
but not over the pigmented area in patient 8.
In patient 4 (37 year old with POHS) a recurrent
submacular haemorrhage was observed ophthalmoscopically
after 13 months. No signs of infection were observed in any
of the patients.
DISCUSSION
For patients with large, occult subfoveal membranes with or
without subretinal blood present, there is no evidence based
treatment available. We have translocated autologous per-
ipheral RPE cells to try and improve both the reported
autologous RPE19 and IPE20 injection approaches: the latter by
choosing RPE cells that may be more likely to take over
macular RPE functions than IPE cells21 22; the former by
harvesting cells in a manner that would allow us both to
collect a greater number of cells and examine these cells for
viability in each patient. As to the site of harvesting RPE we
chose the inferior retina to minimise the handicap of the
resulting scotoma. The disadvantage of having an inferior
retinectomy (while the tamponades used had their major
effect in the superior half of the retina) was partly overcome
by having a formed laser retinopexy at the time of surgery.
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We aspirated a fairly large number of cells which we
showed in a parallel study to be able to survive the
aspiration-centrifuge-injection treatment. On cytospin pre-
paration these cells showed RPE specific staining with
cytokeratin 8/18 monoclonal antibodies (van Meurs et al,
ARVO abstract 2002, no 683). In that study, however, RPE
cells from patients with ARMD (although viable as evaluated
by trypan blue exclusion) were unable to grow to confluence.
The number of cells we analysed per patient for quality
control varied from 12.56103 to 706103, but this number of
analysed cells was only a small portion of the number of cells
actually reinjected. As the average size of the denuded area
after the extraction of the choroidal membrane was
approximately 4 disc areas with an estimated cell number
of 76104 RPE cells,23 the transplanted number of RPE cells
would be sufficient if not excessive to repopulate the
damaged submacular area.
Adhesion of loose clumps of cells to the damaged Bruch’s
membrane is important for their survival24 and is likely to be
a problem for the cells we and others have injected14 19 20; it is
not clear how many of the injected cells managed to settle
and function metabolically and elaborate substances to re-
establish Bruch’s membrane and modulate choriocapillary
growth. We chose to enhance adhesion by the application of a
well known laboratory and graft25 adhesion promotor poly-L-
lysine. We showed in rabbits that poly-L-lysine in the dose
used was not retinotoxic (Stalmans et al, EVER abstract, Las
Palmas 2000).26 It was uncertain, however, whether the
injection of poly-L-lysine had any influence on the adhesion
of the injected RPE cells in our patients.
Several factors may have contributed to the high incidence
of PVR in this study: (1) The creation of a large retinectomy
with aspiration of RPE cells caused a blood-retina barrier
breakdown. (2) Our technique to try and prevent reflux
through the injection site (sealing with PFCL) was probably
not successful: we speculate that at least some RPE cells
injected under macula may have flowed back through the
injection site into the vitreous cavity and contributed to the
development of PVR. (3) The same reflux may have occurred
with poly-L-lysine, which may have enhanced the adherence
of RPE cells to the retina, thereby accelerating PVR. (4) By
selecting an inferior rather than a superior retinectomy site
while using lighter than water tamponades, the retinectomy
was brought into contact with the aqueous phase containing
inflammatory cells and RPE cells.27
The transplantation of autologous cell sheets would
decrease the reflux problem and might increase the chance
of RPE cells survival,16 28 29 but growth on a sheet and a
second operation are challenging in terms of sterility, the
choice of the sheet material used, and the surgical placement
technique.
Signs of a recurrent choroidal membrane were detected
ophthalmoscopically in one patient. As we did not perform
fluorescein angiograms to exclude recurrent membranes and
our follow up was relatively short (12218 months), we may
be underestimating the rate of recurrence.
Disappointingly, translocated RPE cells were ophthalmo-
scopically not detectable in seven patients. Several factors
may have played a part: reflux to the vitreous cavity
preoperatively or postoperatively, because the retinotomy site
was not adequately closed and adhesion of the RPE cells to
an underlayer never occurred; a rapid clearance of the RPE
cells by an inflammmatory reponse secondary to the
mechanical removal of the subretinal membrane; loss of
pigment due to RPE cell proliferation: non-pigmented RPE
cells. Indeed, the pigmentation noted in patient 8 may not be
related to the translocated cells, but may merely be a reaction
to surgical extraction.8 Functionally, vision stabilised in five
patients; fixation was on the edge of the extraction bed in
three patients, but not over the pigmented area in the only
patient with visible pigmentation. In three patients their
decrease of vision was caused by retinal detachment.
In conclusion, although we were able to translocate RPE
cells in a sterile manner, our findings do not support our
assumption that the translocated RPE cells would improve on
the functional results of simple membrane extraction.
Because of the modest results we obtained in the patients
without complications, as well as the severe complications we
encountered in others, we have stopped this approach until
we have learned more about means to promote the survival of
transplanted RPE cells under the macula.
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